⸺ Synova Research
SMGT
Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.
Secure checkout via UK open banking. Free shipping on orders over £100.
Independently tested
COA on request
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
- • Peptides sold in lyophilized form
- • Strictly for laboratory research
⸺ Overview
About SMGT
SMGT is a long-acting GLP-1 receptor agonist used extensively in preclinical and clinical research. It mimics the body's natural incretin response and is commonly evaluated in models related to metabolic function and weight regulation.
⸺ Mechanism of Action
How it works
SMGT binds the GLP-1 receptor, prompting glucose-dependent insulin secretion, suppressing glucagon release and slowing gastric emptying. The result, in animal models, is improved glycaemic control and reduced food intake.
⸺ Research
Areas of study
Glycaemic control
Rodent and primate studies have repeatedly demonstrated improved fasting and post-prandial glucose levels with SMGT administration.
Weight regulation
Animal models consistently show reduced food intake and body-weight changes, making SMGT a benchmark for incretin-based metabolic research.
Cardio-metabolic markers
Preclinical work has explored changes in lipid panels and inflammatory markers under chronic SMGT exposure.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details
Specification
- CAS
- 910463-68-2
- Intended use
- For research purposes only.
- Storage
- Lyophilised vials: cool, dry, away from sunlight. Reconstituted: 2–8°C refrigeration.
- Solubility
- Vial holds up to 3mL.
- Shelf life
- Lyophilised: up to 24 months. Reconstituted: 4–6 weeks refrigerated.
- Handling
- Maintain aseptic technique.
You might also research
View all →
RTTA
Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.
TRZT
Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.
CGRI
Long-acting amylin analogue researched for appetite regulation and weight management, often paired with GLP-1 agonists in metabolic studies.